Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy

Cellular and Molecular Immunology

Volumn 9, Issue 4, 2012, Pages 310-320

  Luevano, Martha ^a   Madrigal, Alejandro ^a   Saudemont, Aurore ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cord blood; differentiation; natural killer cells

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; MONOCLONAL ANTIBODY; RECOMBINANT CYTOKINE;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL DIFFERENTIATION; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CELL SURVIVAL; CELL THERAPY; CELLULAR IMMUNITY; CULTURE TECHNIQUE; DNA MODIFICATION; DRUG MECHANISM; DRUG MEGADOSE; EMBRYONIC STEM CELL; FEEDER CELL; GENE THERAPY; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; IN VITRO STUDY; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NATURAL KILLER CELL; NONHUMAN; REVIEW; SERUM; SOLID TUMOR; STEM CELL MOBILIZATION; STROMA CELL; T LYMPHOCYTE; TUMOR; UMBILICAL CORD BLOOD; VASCULAR DISEASE; VASCULAR LEAK SYNDROME;

ANIMALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY, ADOPTIVE; INFECTION; KILLER CELLS, NATURAL; NEOPLASMS; STEM CELL NICHE;

EID: 84863431090     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2012.17     Document Type: Review

References (130)

1. Kiessling R, Klein E, Pross H, Wigzell H. 'Natural' killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975; 5: 117-121.
2. Kiessling R, Klein E, Wigzell H. 'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5: 112-117.
3. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975; 16: 216-229.
4. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975; 16: 230-239.
5. Lanier LL, Phillips JH, Hackett J Jr, Tutt M, Kumar V. Natural killer cells: Definition of a cell type rather than a function. J Immunol 1986; 137: 2735-2739.
6. Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989; 169: 2233-2238.
7. Ritz J, Schmidt RE, Michon J, Hercend T, Schlossman SF. Characterization of functional surface structures on human natural killer cells. Adv Immunol 1988; 42: 181-211.
8. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640.
9. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T et al. Human natural killer cells: A unique innate immunoregulatory role for the CD56bright subset. Blood 2001; 97: 3146-3151.
10. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675-678.
11. Karre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol 2002; 55: 221-228.
12. Di Santo JP. Natural killer cell developmental pathways: A question of balance. Annu Rev Immunol 2006; 24: 257-286.
13. Colonna M, Brooks EG, Falco M, Ferrara GB, Strominger JL. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 1993; 260: 1121-1124.
14. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
15. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
16. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
17. Takenaka K, Mizuno SI, Harada M, Nagafuji K, Miyamoto T, Iwasaki H et al. Generation of human natural killer cells from peripheral blood CD341 cells mobilized by granulocyte colony-stimulating factor. Br J Haematol 1996; 92: 788-794.
18. Sconocchia G, Provenzano M, Rezvani K, Li J, Melenhorst J, Hensel N et al. CD341 cells cultured in stem cell factor and interleukin-2 generate CD561 cells with antiproliferative effects on tumor cell lines. J Transl Med 2005; 3: 15.
19. Kao IT, Yao CL, Kong ZL, Wu ML, Chuang TL, Hwang SM. Generation of natural killer cells from serum-free, expanded human umbilical cord blood CD341 cells. Stem Cells Dev 2007; 16: 1043-1051.
20. Suck G, Koh MB. Emerging natural killer cell immunotherapies: Large-scale ex vivo production of highly potent anticancer effectors. Hematol Oncol Stem Cell Ther 2010; 3: 135-142.
21. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
22. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
23. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, SherryRMet al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
24. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357.
25. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nature immunology 2002; 3: 999-1005.
26. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 89-95.
27. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850-861.
28. Coghill JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector CD41 T cells, the cytokines they generate, and GVHD: Something old and something new. Blood 2011; 117: 3268-3276.
29. Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009; 114: 2667-2677.
30. BensonDMJr, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 2011; 118: 6387-6391.
31. Robinson BW, Morstyn G. Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-Activated NK cells. Cell Immunol 1987; 106: 215-222.
32. Torelli GF, Guarini A, Palmieri G, Breccia M, Vitale A, Santoni A et al. Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. Br J Haematol 2002; 116: 299-307.
33. Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005; 86: 209-239.
34. Cao S, Wang YL, Ren XB, Yu JP, Ren BZ, ZhangXWet al. Efficacy of large doses of IL-2-Activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma. Cancer Biother Radiopharm 2011; 26: 503-510.
35. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137: 1735-1742.
36. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-2116.
37. Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev 2011; 22: 99-108.
38. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK et al. NK-cell education after allogeneic transplantation: Dissociation between recovery of cytokine producing and cytotoxic functions. Blood 2011; 118: 2784-2792.
39. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
40. Ren XB, Yu JP, Cao S, Ren BZ, Li H, Liu H et al. Antitumor effect of large doses IL-2-Activated HLA haploidentical peripheral blood stem cells on refractory metastatic solid tumor treatment. Cancer Biother Radiopharm 2007; 22: 223-234.
41. Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, Tonn T et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33: 261-266.
42. Pegram HJ, Jackson JT, Smyth MJ, Kershaw MH, Darcy PK. Adoptive transfer of genemodified primaryNKcells can specifically inhibit tumor progression in vivo. J Immunol 2008; 181: 3449-3455.
43. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005; 106: 376-383.
44. Nagashima S, Mailliard R, Kashii Y, Reichert TE, Herberman RB, Robbins P et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 1998; 91: 3850-3861.
45. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial. Cytotherapy 2008; 10: 625-632.
46. Arina A, Murillo O, Dubrot J, Azpilikueta A, Gabari I, Perez-Gracia JL et al. Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells. Gene Ther 2008; 15: 473-483.
47. Grzywacz B, Kataria N, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 2006; 108: 3824-3833.
48. Miller JS, Alley KA, McGlave P. Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: Identification of a CD34171 NK progenitor. Blood 1994; 83: 2594-2601.
49. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev 2006; 214: 56-72.
50. Vacca P, Vitale C, Montaldo E, Conte R, Cantoni C, Fulcheri E et al. CD341 hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci USA 108: 2402-2407.
51. Vosshenrich CA, Garcia-Ojeda ME, Samson-Villeger SI, Pasqualetto V, Enault L, Richard-Le Goff O et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 2006; 7: 1217-1224.
52. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol 2003; 3: 413-425.
53. Ramos SB, Garcia AB, VianaSR , Voltarelli JC, Falcao RP. Phenotypic and functional evaluation of natural killer cells in thymectomized children. Clin Immunol Immunopathol 1996; 81: 277-281.
54. Passlick B, IzbickiJR , Waydhas C, Nast-Kolb D, Schweiberer L, Ziegler-HeitbrockHW. Posttraumatic splenectomy does not influence human peripheral blood mononuclear cell subsets. J Clin Lab Immunol 1991; 34: 157-161.
55. Haller O, Wigzell H. Suppression of natural killer cell activity with radioactive strontium: Effector cells are marrow dependent. J Immunol 1977; 118: 1503-1506.
56. Grzywacz B, Kataria N, Blazar BR, Miller JS, Verneris MR. Natural killer cell differentiation by myeloid progenitors. Blood 2011; 117: 3548-3558.
57. Graf T. Differentiation plasticity of hematopoietic cells. Blood 2002; 99: 3089-3101.
58. Ikawa T, Kawamoto H, Fujimoto S, Katsura Y. Commitment of common T/natural killer (NK) progenitors to unipotent T and NK progenitors in the murine fetal thymus revealed by a single progenitor assay. J Exp Med 1999; 190: 1617-1626.
59. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A et al. IL-15 transpresentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009; 206: 25-34.
60. Kamizono S, Duncan GS, Seidel MG, Morimoto A, Hamada K, Grosveld G et al. Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med 2009; 206: 2977-2986.
61. Gascoyne DM, Long E, Veiga-Fernandes H, De Boer J, Williams O, Seddon B et al. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol 2009; 10: 1118-1124.
62. Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE et al. Flt3 ligand promotes the generation of a distinct CD341 human natural killer cell progenitor that responds to interleukin-15. Blood 1998; 92: 3647-3657.
63. Sivori S, Falco M, Marcenaro E, Parolini S, Biassoni R, Bottino C et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci USA 2002; 99: 4526-4531.
64. Bennett IM, Zatsepina O, Zamai L, Azzoni L, Mikheeva T, Perussia B. Definition of a natural killer NKR-P1A1/CD562/CD162 functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12. J Exp Med 1996; 184: 1845-1856.
65. Lanier LL, Chang C, Phillips JH. Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994; 153: 2417-2428.
66. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25: 331-342.
67. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436: 709-713.
68. Sutlu T, Stellan B, Gilljam M, Quezada HC, Nahi H, Gahrton G et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 2010; 12: 1044-1055.
69. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMPcompliant components. Blood 2008; 111: 3155-3162.
70. Doskali M, Tanaka Y, Ohira M, Ishiyama K, Tashiro H, Chayama K et al. Possibility of adoptive immunotherapy with peripheral blood-derived CD3CD561 and CD31CD561 cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity. J Immunother 2011; 34: 129-138.
71. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69: 4010-4017.
72. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835-1838.
73. Voshol H, Dullens HF, Den Otter W, Vliegenthart JF. Human natural killer cells: A convenient purification procedure and the influence of cryopreservation on cytotoxic activity. J Immunol Methods 1993; 165: 21-30.
74. Fujiwara S, Akiyama M, Yamakido M, Seyama T, Kobuke K, Hakoda M et al. Cryopreservation of human lymphocytes for assessment of lymphocyte subsets and natural killer cytotoxicity. J Immunol Methods 1986; 90: 265-273.
75. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD561 natural killer cells from CD341 hematopoietic progenitor cells. Blood 1996; 87: 2632-2640.
76. Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 2009; 113: 6094-6101.
77. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
78. Allegrucci C, Young LE. Differences between human embryonic stem cell lines. Hum Reprod Update 2007; 13: 103-120.
79. Woll PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol 2005; 175: 5095-5103.
80. Shibuya A, Nagayoshi K, Nakamura K, Nakauchi H. Lymphokine requirement for the generation of natural killer cells from CD341 hematopoietic progenitor cells. Blood 1995; 85: 3538-3546.
81. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunol 2002; 3: 687-694.
82. Giuliani M, Giron-Michel J, Negrini S, Vacca P, Durali D, Caignard A et al. Generation of a novel regulatory NK cell subset from peripheral blood CD341 progenitors promoted by membrane-bound IL-15. PLoS One 2008; 3: E2241.
83. Kalberer CP, Siegler U, Wodnar-Filipowicz A. Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD341 cells. Blood 2003; 102: 127-135.
84. Itoh K, Tezuka H, Sakoda H, Konno M, Nagata K, Uchiyama T et al. Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol 1989; 17: 145-153.
85. Oostendorp RA, Harvey KN, Kusadasi N, De Bruijn MF, Saris C, Ploemacher RE et al. Stromal cell lines from mouse aorta-gonads-mesonephros subregions are potent supporters of hematopoietic stem cell activity. Blood 2002; 99: 1183-1189.
86. Moore KA, Ema H, Lemischka IR. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood 1997; 89: 4337-4347.
87. Miller JS, McCullar V. Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 2001; 98: 705-713.
88. McCullar V, Oostendorp R, Panoskaltsis-Mortari A, Yun G, Lutz CT, Wagner JE et al. Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp Hematol 2008; 36: 598-608.
89. Pierson BA, McGlave PB, Hu WS, Miller JS. Natural killer cell proliferation is dependent on human serum and markedly increased utilizing an enriched supplemented basal medium. J Hematother 1995; 4: 149-158.
90. Pierson BA, Gupta K, Hu WS, Miller JS. Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factorbeta 1 and independent accessory cell-derived contact and soluble factors. Blood 1996; 87: 180-189.
91. Kao IT, Yao CL, Kong ZL, Wu ML, Chuang TL, Hwang SM. Generation of natural killer cells from serum-free, expanded human umbilical cord blood CD341 cells. Stem Cells Dev 2007; 16: 1043-1051.
92. Bonanno G, Mariotti A, Procoli A, Corallo M, Scambia G, Pierelli L et al. Interleukin-21 induces the differentiation of human umbilical cord blood CD342lineage2 cells into pseudomature lytic NK cells. BMC Immunol 2009; 10: 46.
93. Frias AM, Porada CD, Crapnell KB, Cabral JM, Zanjani ED, Almeida-Porada G. Generation of functional natural killer and dendritic cells in a human stromal-based serum-free culture system designed for cord blood expansion. Exp Hematol 2008; 36: 61-68.
94. Williams NS, Klem J, Puzanov IJ, Sivakumar PV, Schatzle JD, BennettMet al. Natural killer cell differentiation: Insights from knockout and transgenic mouse models and in vitro systems. Immunol Rev 1998; 165: 47-61.
95. Williams NS, Moore TA, Schatzle JD, Puzanov IJ, Sivakumar PV, Zlotnik A et al. Generation of lytic natural killer 1.11, Ly2492 cells from multipotential murine bone marrow progenitors in a stroma-free culture: Definition of cytokine requirements and developmental intermediates. J Exp Med 1997; 186: 1609-1614.
96. Williams DE, Eisenman J, Baird A, Rauch C, van Ness K, March CJ et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990; 63: 167-174.
97. Matos ME, Schnier GS, Beecher MS, Ashman LK, William DE, Caligiuri MA. Expression of a functional c-kit receptor on a subset of natural killer cells. J Exper Med 1993; 178: 1079-1084.
98. Colucci F, Di Santo JP. The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells. Blood 2000; 95: 984-991.
99. Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T2B1NK1 severe combined immunodeficiency. Nat Genet 1998; 20: 394-397.
100. Mingari MC, Vitale C, Cantoni C, Bellomo R, Ponte M, Schiavetti F et al. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: Selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. Eur J Immunol 1997; 27: 1374-1380.
101. Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ et al. A human CD341 subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 2005; 22: 295-304.
102. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009; 457: 722-725.
103. Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002; 100: 3633-3638.
104. Gamero AM, Ussery D, Reintgen DS, Puleo CA, Djeu JY. Interleukin 15 induction of lymphokine-Activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res 1995; 55: 4988-4994.
105. Mortier E, Woo T, Advincula R, Gozalo S, Ma A. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 2008; 205: 1213-1225.
106. Lee GA, Liou YH, Wang SW, Ko KL, Jiang ST, Liao NS. DifferentNKcell developmental events require different levels of IL-15 trans-presentation. J Immunol 2011; 187: 1212-1221.
107. Dulphy N, Haas P, Busson M, Belhadj S, Peffault De Latour R, Robin M et al. An unusual CD56brightCD16low NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol 2008; 181: 2227-2237.
108. Beziat V, Duffy D, Quoc SN, Le Garff-Tavernier M, Decocq J, Combadiere B et al. CD56brightCD161 NK cells: A functional intermediate stage of NK cell differentiation. J Immunol 2011; 186: 6753-6761.
109. Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NKcell differentiation uncoupled from NK-cell education. Blood 116: 3853-3864.
110. Berg M, Childs R. Ex-vivo expansion of NKcells: What is the priority-high yield or high purity? Cytotherapy 2010; 12: 969-970.
111. Alici E, Konstantinidis KV, Sutlu T, Aints A, Gahrton G, Ljunggren HG et al. Antimyeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Exp Hematol 2007; 35: 1839-1846.
112. Sutlu T, Alici E. Ex vivo expansion of natural killer cells: A question of function. Cytotherapy 2011; 13: 767-768.
113. Moins-Teisserenc HT, Gadola SD, Cella M, Dunbar PR, Exley A, Blake N et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet 1999; 354: 1598-1603.
114. Schleinitz N, Vely F, Harle JR, Vivier E. Natural killer cells in human autoimmune diseases. Immunology 2010; 131: 451-458.
115. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T et al. NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28: 955-959.
116. Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B et al. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: A phase I clinical study. Immunotherapy 2009; 1: 753-764.
117. Siegler U, Meyer-Monard S, Jorger S, Stern M, Tichelli A, Gratwohl A et al. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy 2010; 12: 750-763.
118. Tanaka J, Sugita J, Shiratori S, Shigematu A, Asanuma S, Fujimoto K et al. Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells. Leukemia; in press
119. Spanholtz J, Tordoir M, Eissens D, Preijers F, van Der Meer A, Joosten I et al. High logscale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One 2010; 5: E9221.
120. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, De Witte T et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 2011; 6: E20740.
121. Escudier B, Farace F, Angevin E, Charpentier F, Nitenberg G, Triebel F et al. Immunotherapy with interleukin-2 (IL2) and lymphokine-Activated natural killer cells: Improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. Eur J Cancer 1994; 30A: 1078-1083.
122. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004; 24: 1861-1871.
123. deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W et al. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother 2000; 23: 154-160.
124. Lister J, Rybka WB, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ et al. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res 1995; 1: 607-614.
125. Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, Tonn T et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Molec Dis 2004; 33: 261-266.
126. Haddad R, Guardiola P, Izac B, Thibault C, Radich J, Delezoide AL et al. Molecular characterization of early human T/NK and B-lymphoid progenitor cells in umbilical cord blood. Blood 2004; 104: 3918-3926.
127. Perez SA, Mahaira LG, Sotiropoulou PA, Gritzapis AD, Iliopoulou EG, Niarchos DK et al. Effect of IL-21 on NK cells derived from different umbilical cord blood populations. Int Immunol 2006; 18: 49-58.
128. Kobari L, Pflumio F, Giarratana M, Li X, Titeux M, Izac B et al. In vitro and in vivo evidence for the long-term multilineage (myeloid, B, NK, and T) reconstitution capacity of ex vivo expanded human CD341 cord blood cells. Exp Hematol 2000; 28: 1470-1480.
129. Beck RC, Padival M, Yeh D, Ralston J, Cooke KR, Lowe JB. The Notch ligands Jagged2, Delta1, and Delta4 induce differentiation and expansion of functional humanNK cells from CD341 cord blood hematopoietic progenitor cells. Biol Blood Marrow Transplant 2009; 15: 1026-1037.
130. Vacca P, Vitale C, Montaldo E, Conte R, Cantoni C, Fulcheri E et al. CD341 hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci US A 2011; 108: 2402-2407.